Use of a synthetic control arm drawn from historical clinical trial data could provide better information about a new investigational agent’s safety and efficacy than single-arm studies and allow sponsors to conduct randomized trials that are smaller, or with more patients assigned to the investigational drug.
External Control Arms: Better Than Single-Arm Studies But No Replacement For Randomization
Synthetic control group derived from historical clinical trial data could augment smaller randomized trials and yield better information than single-arm studies, but this approach should not be viewed as a substitute for randomized trials where feasible, US FDA officials said at a Friends of Cancer Research meeting.
More from Clinical Trials
More from R&D
• By
The European Medicines Agency’s innovation network has recommended how the EU’s regulatory framework could be updated to support drug developers in using new approach methodologies, which are drug testing methods that reduce or replace animal studies.
• By
New plan to encourage alternatives to animal testing seeks interagency cooperation to meet more aggressive targets for transformational change than the US FDA’s long-standing program.
• By
Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.